|
MechanismSARS-CoV-2 Nsp1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
100 Clinical Results associated with SARS-CoV-2 Nsp1
100 Translational Medicine associated with SARS-CoV-2 Nsp1
0 Patents (Medical) associated with SARS-CoV-2 Nsp1